In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
The in vitro activities of CEM-101, telithromycin, azithromycin, clarithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae were tested. The MIC at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by CEM-101 were 0.25 microg/ml (ranges, 0.125 to 0.5 microg/ml for C. trachomatis and 0.25 to 1.0 microg/ml for C. pneumoniae).
Roblin
Patricia M
PM
Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098, USA.
Kohlhoff
Stephan A
SA
Parker
Charles
C
Hammerschlag
Margaret R
MR
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D002690:Chlamydia Infections / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects* / Q000302:isolation & purification; D023521:Chlamydophila Infections / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007223:Infant; D018942:Macrolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000382:microbiology; D014230:Triazoles / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D018942:Macrolides; D014230:Triazoles; C547755:solithromycin